Novo Nordisk A/S (NVO)
Novo Nordisk A/S is a global healthcare company based in Denmark, specializing in the research, development, and manufacturing of pharmaceutical products. The company is a leader in diabetes care and is also involved in areas such as hemophilia care, growth hormone therapy, and hormone replacement therapy. Additionally, Novo Nordisk produces the successful weight loss drug, Wegovy.
Company Info
| ISIN | US6701002056 |
|---|---|
| CUSIP | 670100205 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $451.71B |
|---|---|
| EPS | $2.46 |
| PE Ratio | 41.17 |
| PEG Ratio | 5.25 |
| Revenue (TTM) | $214.49B |
| Gross Profit (TTM) | $148.51B |
| EBITDA (TTM) | $100.11B |
| Year Range | $61.29 - $105.69 |
| Target Price | $103.55 |
| Short % | 0.14% |
| Short Ratio | 1.31 |
Share Price Chart
Loading data...
Performance
The chart shows the growth of an initial investment of $10,000 in Novo Nordisk A/S, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Compare to other instruments
Popular comparisons: NVO vs. LLY, NVO vs. NVS, NVO vs. MRK, NVO vs. POST, NVO vs. VTI, NVO vs. AAPL, NVO vs. VXUS, NVO vs. XLV, NVO vs. VYM, NVO vs. XLF
Return
Novo Nordisk A/S had a return of 51.09% year-to-date (YTD) and 62.13% in the last 12 months. Over the past 10 years, Novo Nordisk A/S had an annualized return of 22.46%, outperforming the S&P 500 benchmark which had an annualized return of 9.87%.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 51.09% | 19.67% |
| 1 month | 2.78% | 8.42% |
| 6 months | 28.65% | 7.29% |
| 1 year | 62.13% | 12.71% |
| 5 years (annualized) | 37.57% | 10.75% |
| 10 years (annualized) | 22.46% | 9.87% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | -3.97% | 0.86% | -0.46% | 16.00% | -2.01% | 6.19% | 5.46% |
Risk-Adjusted Performance
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 2.11 | ||||
^GSPC S&P 500 | 0.91 |
Dividend History
Novo Nordisk A/S granted a 0.73% dividend yield in the last twelve months. The annual payout for that period amounted to $0.74 per share.
| Period | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.74 | $0.57 | $0.52 | $0.46 | $0.44 | $0.45 | $0.41 | $0.52 | $0.27 | $0.30 | $0.23 | $0.18 |
Dividend yield | 0.73% | 0.84% | 0.94% | 1.33% | 1.51% | 1.97% | 1.52% | 2.87% | 0.92% | 1.43% | 1.23% | 1.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Novo Nordisk A/S. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | $0.00 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.00 | $0.31 | $0.00 | $0.00 | $0.00 | |
| 2022 | $0.00 | $0.00 | $0.37 | $0.00 | $0.00 | $0.00 | $0.00 | $0.20 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.33 | $0.00 | $0.00 | $0.00 | $0.00 | $0.19 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2020 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2019 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2018 | $0.00 | $0.00 | $0.29 | $0.00 | $0.00 | $0.00 | $0.00 | $0.16 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2017 | $0.00 | $0.00 | $0.24 | $0.00 | $0.00 | $0.00 | $0.00 | $0.17 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2016 | $0.00 | $0.00 | $0.35 | $0.00 | $0.00 | $0.00 | $0.00 | $0.17 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2015 | $0.00 | $0.00 | $0.27 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2014 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2013 | $0.00 | $0.00 | $0.23 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2012 | $0.18 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Novo Nordisk A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Novo Nordisk A/S was 70.97%, occurring on Oct 26, 1984. Recovery took 1720 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -70.97% | Sep 23, 1983 | 278 | Oct 26, 1984 | 1720 | Aug 26, 1991 | 1998 |
| -45.44% | Aug 4, 2015 | 332 | Nov 23, 2016 | 287 | Jan 17, 2018 | 619 |
| -44.8% | Apr 2, 2002 | 88 | Aug 5, 2002 | 161 | Mar 26, 2003 | 249 |
| -42.51% | Apr 7, 1998 | 241 | Mar 22, 1999 | 3 | Mar 25, 1999 | 244 |
| -40.96% | Apr 9, 2008 | 231 | Mar 9, 2009 | 104 | Aug 5, 2009 | 335 |
Volatility Chart
The current Novo Nordisk A/S volatility is 8.48%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.